Denali Therapeutics (DNLI) Change in Acquisitions & Divestments (2017 - 2026)

Denali Therapeutics (DNLI) has reported Change in Acquisitions & Divestments for 10 consecutive years, with $220.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments rose 36.01% year-over-year to $220.0 million; the TTM figure through Mar 2026 stood at $764.3 million (down 18.32% YoY), while the FY2025 annual figure was $706.0 million, down 38.98% from the prior year.
• Change in Acquisitions & Divestments slipped to $220.0 million in Q1 2026 per DNLI's latest filing, from $275.0 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $601.1 million in Q3 2023 and bottomed at $107.1 million in Q3 2025.
• Historically, Change in Acquisitions & Divestments has averaged $303.0 million across 5 years, with a median of $250.5 million in 2022.
• Annual changes were most pronounced in 2023 — Change in Acquisitions & Divestments jumped 316.46% — and 2024, when it tumbled 67.06%.
• Denali Therapeutics' Change in Acquisitions & Divestments stood at $364.0 million in 2022, then soared by 34.34% to $489.0 million in 2023, then fell by 28.22% to $351.0 million in 2024, then fell by 21.65% to $275.0 million in 2025, then slipped by 20.0% to $220.0 million in 2026.
• Business Quant data shows DNLI's Change in Acquisitions & Divestments at $220.0 million in Q1 2026, $275.0 million in Q4 2025, and $107.1 million in Q3 2025.